Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MediciNova halts Phase 2 trial
May 2018
SHARING OPTIONS:

LA JOLLA, Calif.—Early April saw MediciNova Inc. announce the early termination of its Phase 2 clinical trial of MN-001 in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with hypertriglyceridemia, due to positive results from the interim analysis. The compound significantly reduced mean serum triglycerides—a primary endpoint—from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment, with no clinically significant safety or tolerability issues. MediciNova plans to accelerate development of MN-001 given these results.
 
Dr. Yuichi Iwaki, president and CEO of MediciNova, remarked that, “We are thrilled with the results of this study, which showed a large reduction in triglycerides. Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.